NCT00436787View on ClinicalTrials.gov

Investigation Into the Therapeutic Dosage of Fondaparinux Sodium, a Medication Used to Prevent Blood Clots in Morbidly Obese Volunteers

PHASE2CompletedINTERVENTIONAL

Enrollment

21

Participants

Timeline

Start Date

February 28, 2007

Study Completion Date

December 31, 2007

Conditions

Venous ThrombosisPulmonary Embolism

Interventions

DRUG

Fondaparinux Sodium

Trial Locations (2)

15213

Magee Women's Hospital, Pittsburgh

15232

Shadyside Medical Building, Pittsburgh

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

University of Pittsburgh

OTHER

NCT00436787 - Investigation Into the Therapeutic Dosage of Fondaparinux Sodium, a Medication Used to Prevent Blood Clots in Morbidly Obese Volunteers | Biotech Hunter | Biotech Hunter